Jacqueline Zummo Sells 21,224 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) Stock

Protara Therapeutics, Inc. (NASDAQ:TARA) insider Jacqueline Zummo sold 21,224 shares of the stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total transaction of $96,144.72. Following the sale, the insider now directly owns 98,861 shares in the company, valued at $447,840.33. This represents a 17.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Protara Therapeutics Trading Up 0.9 %

Shares of TARA stock opened at $4.58 on Friday. The company has a market cap of $168.39 million, a PE ratio of -1.62 and a beta of 1.69. The company’s fifty day simple moving average is $4.27 and its 200-day simple moving average is $3.66. Protara Therapeutics, Inc. has a 52 week low of $1.60 and a 52 week high of $10.48.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings data on Wednesday, March 12th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.09. Equities research analysts expect that Protara Therapeutics, Inc. will post -3.32 EPS for the current fiscal year.

Institutional Trading of Protara Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd acquired a new position in Protara Therapeutics during the 3rd quarter worth $60,000. HBK Investments L P acquired a new stake in Protara Therapeutics during the fourth quarter valued at $106,000. Squarepoint Ops LLC acquired a new position in Protara Therapeutics during the fourth quarter worth $110,000. Dimensional Fund Advisors LP bought a new position in Protara Therapeutics in the 4th quarter worth $111,000. Finally, Bailard Inc. bought a new position in shares of Protara Therapeutics during the 4th quarter worth about $157,000. 38.13% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TARA has been the subject of several analyst reports. Cantor Fitzgerald started coverage on Protara Therapeutics in a research report on Friday, March 14th. They set an “overweight” rating for the company. HC Wainwright reiterated a “buy” rating and set a $23.00 target price on shares of Protara Therapeutics in a research note on Thursday, March 6th. Guggenheim restated a “buy” rating and set a $20.00 price objective on shares of Protara Therapeutics in a research report on Friday, December 6th. Finally, Lifesci Capital started coverage on Protara Therapeutics in a report on Tuesday, March 11th. They set an “outperform” rating and a $22.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $22.50.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.